Most patients with appendix cancer may avoid chemotherapy after surgery, study suggests
A study from MD Anderson Cancer Center suggests that most patients with localized appendix cancer may not require chemotherapy after surgery. Researchers found low recurrence rates and no significant survival benefit from post-surgical chemotherapy, indicating a need for more personalized treatment approaches.
Why it matters
This could spare many patients from the unnecessary side effects and costs of chemotherapy by shifting clinical practice toward more targeted, evidence-based monitoring.
by University of Texas MD Anderson Cancer Center
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pixabay/CC0 Public Domain Most patients with localized appendix cancer may be able to safely avoid chemotherapy after surgery, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
The study, published in JAMA Surgery , found that fewer than 10% of patients experienced recurrence after surgery, and chemotherapy given after surgery was not associated with improved survival or a lower risk of relapse, even among patients considered higher risk. Researchers also identified specific tumor characteristics and genomic alterations that may help doctors better predict which patients are most likely to see their cancer return.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in